This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

VX-765

Vertex Pharmaceuticals Incorporated

Drug Names(s): VX-765

Description: VX-765 is an oral interleukin-1 beta converting enzyme (ICE, also called caspase-1) inhibitor.

Interleukin-1 is a cytokine involved in various immune responses, inflammatory processes, and the formation of blood cellular components.

In addition, there is increased IL-1 expression in the brain tissue from epilepsy patients and animal models after seizures, and IL-1 has proconvulsive properties when applied exogeneously. However, there have been opposing results found as well, so its role in seizure generation is still unclear.


VX-765 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug